INBRX-109 + carboplatin + pemetrexed

This is a **combination therapy** consisting of INBRX-109 (ozekibart), carboplatin, and pemetrexed. - **INBRX-109** is a recombinant humanized tetravalent monoclonal antibody that acts as an agonist for death receptor 5 (DR5), a proapoptotic receptor highly expressed in many solid tumors[1][2][3][5][6]. By clustering and activating DR5, INBRX-109 induces apoptosis through the extrinsic pathway, promoting tumor-biased cell death via activation of caspase-8 and downstream executioner caspases (caspase-3 and caspase-7)[2][6]. - **Carboplatin** is a small molecule platinum-based chemotherapeutic agent that causes DNA crosslinks and induces DNA damage, leading to apoptosis in rapidly dividing cancer cells. - **Pemetrexed** is a small molecule multitargeted antifolate that inhibits several enzymes involved in folate metabolism and DNA synthesis, blocking tumor cell proliferation. This combination is under clinical investigation in metastatic solid tumors, including **Ewing sarcoma**[6].

Brand names

ozekibart

Other names

ozekibart + carboplatin + pemetrexed